{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:19:40Z","timestamp":1765484380348},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Qingdao Medical Research Guidance Program","award":["WJZD113"],"award-info":[{"award-number":["WJZD113"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The most prevalent mutation in ovarian cancer is the TP53 mutation, which impacts the development and prognosis of the disease. We looked at how the TP53 mutation associates the immunophenotype of ovarian cancer and the prognosis of the disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We investigated the state of TP53 mutations and expression profiles in culturally diverse groups and datasets and developed an immune infiltration predictive model relying on immune-associated genes differently expressed between TP53 WT and TP53 MUT ovarian cancer cases. We aimed to construct an immune infiltration predictive model (IPM) to enhance the prognosis of ovarian cancer and investigate the impact of the IPM on the immunological microenvironment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>TP53 mutagenesis affected the expression of seventy-seven immune response-associated genes. An IPM was implemented and evaluated on ovarian cancer patients to distinguish individuals with low- and high-IPM subgroups of poor survival. For diagnostic and therapeutic use, a nomogram is thus created. According to pathway enrichment analysis, the pathways of the human immune response and immune function abnormalities were the most associated functions and pathways with the IPM genes. Furthermore, patients in the high-risk group showed low proportions of macrophages M1, activated NK cells, CD8<jats:sup>+<\/jats:sup> T cells, and higher CTLA-4, PD-1, PD-L1, and TIM-3 than patients in the low-risk group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The IPM model may identify high-risk patients and integrate other clinical parameters to predict their overall survival, suggesting it is a potential methodology for optimizing ovarian cancer prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-023-01657-x","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:02:22Z","timestamp":1695862942000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Establishment and validation of an immune infiltration predictive model for ovarian cancer"],"prefix":"10.1186","volume":"16","author":[{"given":"Zhenxia","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongmin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"issue":"1","key":"1657_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"7633","key":"1657_CR2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633):433\u20137.","journal-title":"Nature"},{"issue":"4","key":"1657_CR3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng.3225","volume":"47","author":"A Calon","year":"2015","unstructured":"Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, Sevillano M, Palomo-Ponce S, Tauriello DV, Byrom D, Cortina C, Morral C, Barcel\u00f3 C, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47(4):320\u20139.","journal-title":"Nat Genet"},{"issue":"2","key":"1657_CR4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.coi.2013.03.004","volume":"25","author":"H Angell","year":"2013","unstructured":"Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261\u20137.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"1657_CR5","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, Diehn M, West RB, Plevritis SK, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345.","journal-title":"Nat Med"},{"issue":"20 Pt 1","key":"1657_CR6","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106\u201315.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1657_CR7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.2009.27.2369","volume":"29","author":"LE Kandalaft","year":"2011","unstructured":"Kandalaft LE, Powell DJ Jr, Singh N, Coukos G. Immunotherapy for ovarian cancer: what\u2019s next? J Clin Oncol. 2011;29(7):925\u201333.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1657_CR8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.","journal-title":"Cancer Cell."},{"issue":"9","key":"1657_CR9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1657_CR10","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-11-2725","volume":"18","author":"K Yoshihara","year":"2012","unstructured":"Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res. 2012;18(5):1374\u201385.","journal-title":"Clin Cancer Res"},{"issue":"4901","key":"1657_CR11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.2649981","volume":"244","author":"SJ Baker","year":"1989","unstructured":"Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244(4901):217\u201321.","journal-title":"Science"},{"issue":"4929","key":"1657_CR12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1126\/science.2554494","volume":"246","author":"T Takahashi","year":"1989","unstructured":"Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989;246(4929):491\u20134.","journal-title":"Science"},{"issue":"7471","key":"1657_CR13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MDM, Miller CA, Welch JS, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333\u20139.","journal-title":"Nature"},{"issue":"6024","key":"1657_CR14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1126\/science.1204040","volume":"331","author":"MR Stratton","year":"2011","unstructured":"Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011;331(6024):1553\u20138.","journal-title":"Science"},{"issue":"2","key":"1657_CR15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10495-006-0571-1","volume":"12","author":"PB Lai","year":"2007","unstructured":"Lai PB, Chi TY, Chen GG. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis. 2007;12(2):387\u201393.","journal-title":"Apoptosis"},{"issue":"1","key":"1657_CR16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgw118","volume":"38","author":"CV Rao","year":"2017","unstructured":"Rao CV, Asch AS, Yamada HY. Frequently mutated genes\/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 2017;38(1):2\u201311.","journal-title":"Carcinogenesis"},{"issue":"19","key":"1657_CR17","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/onc.2013.201","volume":"33","author":"AL Manning","year":"2014","unstructured":"Manning AL, Benes C, Dyson NJ. Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation. Oncogene. 2014;33(19):2487\u201394.","journal-title":"Oncogene"},{"issue":"10","key":"1657_CR18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc2693","volume":"9","author":"R Brosh","year":"2009","unstructured":"Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009;9(10):701\u201313.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"1657_CR19","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, Ceccarelli M, Bontempi G, Noushmehr H. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71.","journal-title":"Nucleic Acids Res."},{"issue":"7693","key":"1657_CR20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"issue":"1","key":"1657_CR21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016;165(1):35\u201344.","journal-title":"Cell"},{"issue":"23","key":"1657_CR22","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1093\/bioinformatics\/btm369","volume":"23","author":"A Subramanian","year":"2007","unstructured":"Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: A desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007;23(23):3251\u20133.","journal-title":"Bioinformatics"},{"issue":"4","key":"1657_CR23","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812-830 e814.","journal-title":"Immunity."},{"issue":"10","key":"1657_CR24","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"key":"1657_CR25","doi-asserted-by":"crossref","unstructured":"Aran D, Hu Z and Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18.(1):220.","DOI":"10.1186\/s13059-017-1349-1"},{"issue":"5","key":"1657_CR26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"1","key":"1657_CR27","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.","journal-title":"Nat Commun"},{"issue":"Database issue","key":"1657_CR28","first-page":"D955","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955-961.","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"1657_CR29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ygyno.2013.06.016","volume":"130","author":"KK Wong","year":"2013","unstructured":"Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol. 2013;130(3):565\u20139.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1657_CR30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00281-019-00744-5","volume":"41","author":"M Kurachi","year":"2019","unstructured":"Kurachi M. CD8(+) T cell exhaustion. Semin Immunopathol. 2019;41(3):327\u201337.","journal-title":"Semin Immunopathol"},{"key":"1657_CR31","doi-asserted-by":"crossref","first-page":"612139","DOI":"10.3389\/fimmu.2021.612139","volume":"12","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Chen S, Li Q, Liang J, Lin W, Li J, Liu Z, Wen M, Cao M, Hong J. TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration. Front Immunol. 2021;12:612139.","journal-title":"Front Immunol"},{"key":"1657_CR32","doi-asserted-by":"crossref","first-page":"805184","DOI":"10.3389\/fimmu.2022.805184","volume":"13","author":"T Wang","year":"2022","unstructured":"Wang T, Li T, Li B, Zhao J, Li Z, Sun M, Li Y, Zhao Y, Zhao S, He W, Guo X, Ge R, Wang L, et al. Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures. Front Immunol. 2022;13:805184.","journal-title":"Front Immunol"},{"issue":"D1","key":"1657_CR33","doi-asserted-by":"crossref","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587-d592.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1657_CR34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49\u201356.","journal-title":"J Pathol"},{"issue":"2","key":"1657_CR35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/path.2744","volume":"222","author":"M K\u00f6bel","year":"2010","unstructured":"K\u00f6bel M, Reuss A, du Bois A, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010;222(2):191\u20138.","journal-title":"J Pathol"},{"issue":"2","key":"1657_CR36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.bjc.6604471","volume":"99","author":"P de Graeff","year":"2008","unstructured":"de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer. 2008;99(2):341\u20139.","journal-title":"Br J Cancer"},{"issue":"8","key":"1657_CR37","doi-asserted-by":"crossref","first-page":"e72609","DOI":"10.1371\/journal.pone.0072609","volume":"8","author":"HJ Kang","year":"2013","unstructured":"Kang HJ, Chun SM, Kim KR, Sohn I, Sung CO. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. PLoS One. 2013;8(8):e72609.","journal-title":"PLoS One"},{"key":"1657_CR38","doi-asserted-by":"crossref","unstructured":"Silwal-Pandit L, Langer\u00f8d A and B\u00f8rresen-Dale AL. TP53 Mutations in Breast and Ovarian Cancer. Cold Spring Harb Perspect Med. 2017;7(1):a026252.","DOI":"10.1101\/cshperspect.a026252"},{"issue":"12","key":"1657_CR39","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, Tu HY, Chen HJ, Sun YL, Zhou Q, Yang JJ, Yang XN, Lin JX, et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017;23(12):3012\u201324.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1657_CR40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/0008-5472.CAN-20-1674","volume":"81","author":"C Wan","year":"2021","unstructured":"Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K, Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, et al. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021;81(1):158\u201373.","journal-title":"Cancer Res"},{"issue":"3","key":"1657_CR41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/SLA.0000000000002116","volume":"267","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Zhang Q, Hu Y, Li T, Yu J, Zhao L, Ye G, Deng H, Mou T, Cai S, Zhou Z, Liu H, Chen G, et al. ImmunoScore Signature: a Prognostic and Predictive Tool in Gastric Cancer. Ann Surg. 2018;267(3):504\u201313.","journal-title":"Ann Surg"},{"issue":"11","key":"1657_CR42","doi-asserted-by":"crossref","first-page":"e1356147","DOI":"10.1080\/2162402X.2017.1356147","volume":"6","author":"Y Li","year":"2017","unstructured":"Li Y, Lu Z, Che Y, Wang J, Sun S, Huang J, Mao S, Lei Y, Chen Z, He J. Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. Oncoimmunology. 2017;6(11):e1356147.","journal-title":"Oncoimmunology"},{"issue":"9","key":"1657_CR43","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1089\/dna.2020.5596","volume":"39","author":"J Zhang","year":"2020","unstructured":"Zhang J, Zhang Q, Zhang J, Wang Q. Expression of ACAP1 Is Associated with Tumor Immune Infiltration and Clinical Outcome of Ovarian Cancer. DNA Cell Biol. 2020;39(9):1545\u201357.","journal-title":"DNA Cell Biol"},{"issue":"7","key":"1657_CR44","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/annonc\/mdz166","volume":"30","author":"SL Gaillard","year":"2019","unstructured":"Gaillard SL, Coleman RL. Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark? Ann Oncol. 2019;30(7):1025\u20138.","journal-title":"Ann Oncol"},{"issue":"Suppl 24","key":"1657_CR45","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1002\/cncr.32595","volume":"125","author":"R Arend","year":"2019","unstructured":"Arend R, Martinez A, Szul T, Birrer MJ. Biomarkers in ovarian cancer: to be or not to be. Cancer. 2019;125(Suppl 24):4563\u201372.","journal-title":"Cancer"},{"issue":"4","key":"1657_CR46","first-page":"959","volume":"86","author":"MS Bajaj","year":"2001","unstructured":"Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 2001;86(4):959\u201372.","journal-title":"Thromb Haemost"},{"issue":"7","key":"1657_CR47","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-2007-991531","volume":"33","author":"A Amirkhosravi","year":"2007","unstructured":"Amirkhosravi A, Meyer T, Amaya M, Davila M, Mousa SA, Robson T, Francis JL. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost. 2007;33(7):643\u201352.","journal-title":"Semin Thromb Hemost"},{"key":"1657_CR48","doi-asserted-by":"crossref","unstructured":"Yilmaz A, Loustau T, Salom\u00e9 N, Poilil Surendran S, Li C, Tucker RP, Izzi V, Lamba R, Koch M and Orend G. Advances on the roles of tenascin-C in cancer. J Cell Sci. 2022;135(18):jcs260244.","DOI":"10.1242\/jcs.260244"},{"issue":"1\u20132","key":"1657_CR49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1080\/19336918.2015.1008332","volume":"9","author":"T Yoshida","year":"2015","unstructured":"Yoshida T, Akatsuka T, Imanaka-Yoshida K. Tenascin-C and integrins in cancer. Cell Adh Migr. 2015;9(1\u20132):96\u2013104.","journal-title":"Cell Adh Migr"},{"issue":"9","key":"1657_CR50","doi-asserted-by":"crossref","first-page":"980","DOI":"10.4251\/wjgo.v13.i9.980","volume":"13","author":"M Fujita","year":"2021","unstructured":"Fujita M, Suzuki H, Fukai F. Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression. World J Gastrointest Oncol. 2021;13(9):980\u201394.","journal-title":"World J Gastrointest Oncol"},{"issue":"2","key":"1657_CR51","doi-asserted-by":"crossref","first-page":"113402","DOI":"10.1016\/j.yexcr.2022.113402","volume":"421","author":"Y Yang","year":"2022","unstructured":"Yang Y, Cao L, Guo Z, Gu H, Zhang K, Qiu Z. Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD). Exp Cell Res. 2022;421(2):113402.","journal-title":"Exp Cell Res"},{"key":"1657_CR52","doi-asserted-by":"crossref","unstructured":"Lee M, Cho HJ, Park KS and Jung HY. ELK3 Controls Gastric Cancer Cell Migration and Invasion by Regulating ECM Remodeling-Related Genes. Int J Mol Sci. 2022;23(7):3709.","DOI":"10.3390\/ijms23073709"},{"issue":"1","key":"1657_CR53","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1038\/s41598-019-44828-6","volume":"9","author":"KS Kim","year":"2019","unstructured":"Kim KS, Park JI, Oh N, Cho HJ, Park JH, Park KS. ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs. Sci Rep. 2019;9(1):8418.","journal-title":"Sci Rep"},{"issue":"30","key":"1657_CR54","doi-asserted-by":"crossref","first-page":"e29544","DOI":"10.1097\/MD.0000000000029544","volume":"101","author":"H Xu","year":"2022","unstructured":"Xu H, Zhang L, Gao J, Wang J, Wang Y, Xiao D, Chai S. Molecular and clinical features of a potential immunotherapy target ELK3 in glioma. Medicine (Baltimore). 2022;101(30):e29544.","journal-title":"Medicine (Baltimore)"},{"key":"1657_CR55","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","volume":"12","author":"P Matzinger","year":"1994","unstructured":"Matzinger P. Tolerance, danger, and the extended family. Ann Rev Immunol. 1994;12:991\u20131045.","journal-title":"Ann Rev Immunol"},{"issue":"6024","key":"1657_CR56","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370.","journal-title":"Science"},{"issue":"4","key":"1657_CR57","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1084\/jem.20061699","volume":"204","author":"S Loeser","year":"2007","unstructured":"Loeser S, Loser K, Bijker MS, Rangachari M, van der Burg SH, Wada T, Beissert S, Melief CJ, Penninger JM. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med. 2007;204(4):879\u201391.","journal-title":"J Exp Med"},{"issue":"5","key":"1657_CR58","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.4049\/jimmunol.164.5.2619","volume":"164","author":"S Radoja","year":"2000","unstructured":"Radoja S, Rao TD, Hillman D, Frey AB. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. Journal of immunology (Baltimore, Md: 1950). 2000;164(5):2619\u201328.","journal-title":"Journal of immunology (Baltimore, Md: 1950)"},{"issue":"11","key":"1657_CR59","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991\u20138.","journal-title":"Nat Immunol"},{"key":"1657_CR60","doi-asserted-by":"crossref","first-page":"940551","DOI":"10.3389\/fcell.2022.940551","volume":"10","author":"L Yu","year":"2022","unstructured":"Yu L, Liu X, Wang X, Yan H, Pu Q, Xie Y, Du J, Yang Z. Glycometabolism-related gene signature of hepatocellular carcinoma predicts prognosis and guides immunotherapy. Front Cell Dev Biol. 2022;10:940551.","journal-title":"Front Cell Dev Biol"},{"key":"1657_CR61","doi-asserted-by":"crossref","first-page":"799455","DOI":"10.3389\/fimmu.2021.799455","volume":"12","author":"C Genova","year":"2021","unstructured":"Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, Gangemi R, Filaci G, Coco S, Croce M. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Front Immunol. 2021;12:799455.","journal-title":"Front Immunol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01657-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T22:34:34Z","timestamp":1700519674000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01657-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1657"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01657-x","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Collections of human samples were obtained and approved by the ethics committee of Tian Jin Fifth\u2019s Central Hospital. Written informed consent was obtained from individual or guardian participants. All methods were performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}